OTCMKTS:ATRX Adhera Therapeutics (ATRX) Stock Price, News & Analysis → The Best Stock Trading for Less Than $10 Per Share? (From Eagle Publishing) (Ad) Free ATRX Stock Alerts $0.0043 0.00 (0.00%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$0.0043▼$0.004350-Day Range$0.0038▼$0.012052-Week Range$0.00▼$0.08VolumeN/AAverage Volume41,234 shsMarket Capitalization$50,009.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Get Adhera Therapeutics alerts: Email Address Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About Adhera Therapeutics Stock (OTCMKTS:ATRX)Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.Read More ATRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATRX Stock News HeadlinesJanuary 30, 2024 | investing.comAdhera Therapeutics Inc (ATRX)August 24, 2023 | seekingalpha.comATRX Adhera Therapeutics, Inc.May 22, 2023 | seekingalpha.comIntensity Therapeutics upsizes proposed IPO to $15M from $8MFebruary 27, 2023 | finance.yahoo.comAdhera Therapeutics, Inc. (ATRX)January 25, 2023 | finance.yahoo.comAdhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesJanuary 18, 2023 | seekingalpha.comCGTX Cognition Therapeutics, Inc.December 5, 2022 | seekingalpha.comAdhera Therapeutics files for Nasdaq uplisting, $35M offeringOctober 9, 2022 | benzinga.comAdhera Therapeutics Stock (OTC:ATRXD), Analyst Ratings, Price Targets, PredictionsSeptember 21, 2022 | benzinga.comAdhera Therapeutics Announces CEO, Senior...September 19, 2022 | finance.yahoo.comAdhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ UplistSeptember 19, 2022 | seekingalpha.comAdhera Therapeutics gains on announcing CEO, senior management changes, plans for NASDAQ uplistJuly 19, 2022 | finance.yahoo.comAdhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium TransferrinMay 19, 2022 | seekingalpha.comAdhera Therapeutics appoints new Chairman of the Board, focuses on uplist to NasdaqMay 19, 2022 | finance.yahoo.comAdhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQJanuary 20, 2022 | finance.yahoo.comAdhera Therapeutics Announces Uplisting to OTCQB Venture MarketplaceNovember 22, 2021 | finance.yahoo.comAdhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related DisordersNovember 8, 2021 | finance.yahoo.comAdhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of DirectorsOctober 20, 2021 | apnews.comAdhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary ...October 20, 2021 | finance.yahoo.comAdhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target IndicationsOctober 16, 2021 | apnews.comManufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s ...October 15, 2021 | finance.yahoo.comManufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s DiseaseOctober 4, 2021 | finance.yahoo.comAdhera Receives European Patent Covering MLR-1019 and Derivatives for Treating DyskinesiasSeptember 15, 2021 | insidermonkey.com5 Penny Stocks with Upcoming Growth CatalystsSeptember 13, 2021 | apnews.comAdhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease ...September 13, 2021 | finance.yahoo.comAdhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes DrugsSee More Headlines Receive ATRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ATRX CUSIPN/A CIK737207 Webadherathera.com Phone919-518-3748Fax206-830-9424Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,110,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-5,805.73% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($7.02) per share Price / Book0.00Miscellaneous Outstanding Shares11,630,000Free Float8,348,000Market Cap$50,009.00 OptionableNot Optionable Beta-0.30 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Andrew Albert Kucharchuk M.B.A. (Age 43)Vice Chairman, COO, Acting CFO & Chief Business Officer Comp: $285kKey CompetitorsAmpio PharmaceuticalsNYSE:AMPEOrexigen TherapeuticsOTCMKTS:OREXQCalithera BiosciencesNASDAQ:CALARegeneRx BiopharmaceuticalsOTCMKTS:RGRXGenerex BiotechnologyOTCMKTS:GNBTView All Competitors ATRX Stock Analysis - Frequently Asked Questions How have ATRX shares performed in 2024? Adhera Therapeutics' stock was trading at $0.03 at the start of the year. Since then, ATRX stock has decreased by 85.7% and is now trading at $0.0043. View the best growth stocks for 2024 here. When did Adhera Therapeutics' stock split? Shares of Adhera Therapeutics reverse split before market open on Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Adhera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adhera Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). How do I buy shares of Adhera Therapeutics? Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ATRX) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adhera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adhera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.